| For: | Huang XM, Zhong X, Du YJ, Guo YY, Pan TR. Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients. World J Diabetes 2023; 14(8): 1280-1288 [PMID: 37664475 DOI: 10.4239/wjd.v14.i8.1280] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i8/1280.htm |
| Number | Citing Articles |
| 1 |
Tirzepatide a novel anti diabetic molecule unfold dual action. Discover Public Health 2024; 21(1) doi: 10.1186/s12982-024-00200-2
|
| 2 |
Е. L. Nasonov, Т. S. Panevin, Е. А. Troshina. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Rheumatology Science and Practice 2024; 62(2) doi: 10.47360/1995-4484-2024-135-144
|
| 3 |
Fan Yang, Lenian Zhou, Jieyuan Zhang, Qiuke Wang, Qianying Cai, Jiazheng Wang, Chenglin Wu, Xueqian Li, Jinshan Zhang, Yongqiang Zheng, Xin Ma, Hongyi Zhu, Zhongmin Shi. Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study. International Journal of Surgery 2025; 111(12) doi: 10.1097/JS9.0000000000003156
|
| 4 |
Filippo Leggieri, Simon N. van Laarhoven, Vicente J. León Muñoz, Joaquin Moya-Angeler, Mustafa Akkaya, Roberto Civinini, Matteo Innocenti. No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty. Journal of Bone and Joint Surgery 2026; 108(9) doi: 10.2106/JBJS.25.00879
|